Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by stockman75on Oct 01, 2019 1:03pm

154 Views

Post# 30182763

RE:RE:RE:RE:RE:RE:RE:RE:taimed sales september

JFM, your math is close. 18% quarterly is actually less than 6% monthly due to the compounding effect. 18% quarterly equates to about 94% annual growth. 6% monthly gets you to just over 100% annual growth. 19% quareterly gets you to the 100% annual growth.

jfm1330 wrote: 6% monthly growth or 18% quaterly growth gives around 100% yearly growth. Correct me if I'm wrong on that .

Up to now, Trogarzo is behaving pretty much the way the Nature article is describing for such a drug

11% of peak sales in the first year (300 patients)
30% of peak sales after two years (900 patients)

Then it would double in the third year to 60% of peak sales or 1800 patients.

Trogarzo won't match perfectly with that, but if it follows a similar trend, Trogarzo in the US will at lest reach the good scenario we were hoping for of at least 2000 patients, but there is a good probability that it will be much better than that.

https://twitter.com/natrevdrugdisc/status/806161560221708290